XML 100 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Nature of Business and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
3 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Customer
Dec. 31, 2011
Customer
Jan. 14, 2014
Subsequent Event
Dec. 31, 2013
Net product sales
Customer
Dec. 31, 2013
Net product sales
Customer One Product Sales
Dec. 31, 2013
Net product sales
Customer Two Product Sales
Dec. 31, 2013
Net product sales
Customer Three Product Sales
Dec. 31, 2013
Net product sales
Outside the United States
Dec. 31, 2013
Accounts receivable
Customer
Dec. 31, 2013
Accounts receivable
Customer One Product Sales
Dec. 31, 2013
Accounts receivable
Customer Two Product Sales
Dec. 31, 2013
Minimum
Dec. 31, 2013
Maximum
Schedule Of Significant Accounting Policies [Line Items]                              
Realized and unrealized foreign currency transaction losses recognized in earnings   $ 194,000                          
Property and equipment, useful life                           3 years 10 years
Capitalized costs, amortization period maximum                             17 years
Accrued rent 5,100,000 5,100,000 5,000,000                        
Accrued rent included in other long term liabilities 4,600,000 4,600,000 4,700,000                        
Accrued rent included in other current liabilities 500,000 500,000 300,000                        
Amount owed to former customer due to product returns   4,200,000                          
Customer prepayments 8,800,000 8,800,000                          
Value of shipment not recognized as revenue 4,100,000                            
Payment received on shipment 1,800,000 1,800,000                          
Number of customers accounted for net product sales           3                  
Number Of customers accounted for accounts receivable                     2        
Customers concentration risk, percentage             24.00% 15.00% 13.00% 9.00%   15.00% 13.00%    
Number of customers related to revenue     1 1                      
Advertising costs   1,000,000                          
Tax benefit, minimum percentage of likelihood of being realized upon ultimate settlement   50.00%                          
Milestone payments for clinical trials         $ 3,800,000